tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARCT Stock Latest News

Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
The FlyArcturus Therapeutics price target lowered to $21 from $66 at Canaccord
4d ago
ARCT
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
PremiumCompany Announcements
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
4d ago
ARCT
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
PremiumCompany Announcements
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
4d ago
ARCT
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
PremiumThe Fly
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
5d ago
ARCT
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
PremiumRatings
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
5d ago
ARCT
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
PremiumRatingsValidating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
5d ago
ARCT
Arcturus Therapeutics price target raised to $8 from $7 at Citi
Premium
The Fly
Arcturus Therapeutics price target raised to $8 from $7 at Citi
5d ago
ARCT
Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
Premium
The Fly
Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
5d ago
ARCT
Options Volatility and Implied Earnings Moves Today, March 03, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 03, 2026
6d ago
AZO
BBY
ARCT Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ARCT Earnings this Week: How Will it Perform?
8d ago
ARCT
Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
PremiumCompany Announcements
Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
1M ago
ARCT
Arcturus Therapeutics initiated with a Buy at Roth Capital
PremiumThe Fly
Arcturus Therapeutics initiated with a Buy at Roth Capital
2M ago
ARCT
Arcturus Therapeutics price target lowered to $7 from $9 at Citi
PremiumThe FlyArcturus Therapeutics price target lowered to $7 from $9 at Citi
2M ago
ARCT
Arcturus Therapeutics files $500M mixed securities shelf
Premium
The Fly
Arcturus Therapeutics files $500M mixed securities shelf
2M ago
ARCT
Arcturus Therapeutics Announces CFO Departure and Replacement
Premium
Company Announcements
Arcturus Therapeutics Announces CFO Departure and Replacement
3M ago
8K
ARCT
Arcturus Therapeutics price target lowered to $9 from $12 at Citi
PremiumThe Fly
Arcturus Therapeutics price target lowered to $9 from $12 at Citi
4M ago
ARCT
Arcturus Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
PremiumRatings
Arcturus Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
4M ago
ARCT
Arcturus Therapeutics Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Arcturus Therapeutics Earnings Call: Progress Amid Challenges
4M ago
ARCT
Arcturus Therapeutics price target lowered to $72 from $140 at Piper Sandler
PremiumThe Fly
Arcturus Therapeutics price target lowered to $72 from $140 at Piper Sandler
4M ago
ARCT
Arcturus Therapeutics Reports Q3 2025 Financials and Pipeline Progress
PremiumCompany AnnouncementsArcturus Therapeutics Reports Q3 2025 Financials and Pipeline Progress
4M ago
ARCT
Arcturus Therapeutics reports Q3 EPS (49c), consensus (80c)
Premium
The Fly
Arcturus Therapeutics reports Q3 EPS (49c), consensus (80c)
4M ago
ARCT
Arcturus Therapeutics options imply 11.1% move in share price post-earnings
Premium
The Fly
Arcturus Therapeutics options imply 11.1% move in share price post-earnings
4M ago
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >